- Home
- GFUZ vs OVID Comparison
GFUZ vs OVID Comparison
Compare GFUZ & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GFUZ | OVID |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.0M | 562.5M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GFUZ | OVID |
|---|---|---|
| Price | $7.56 | $2.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $5.92 |
| AVG Volume (30 Days) | 98.6K | ★ 1.4M |
| Earning Date | 12-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $6.08 | $1.18 |
| 52 Week High | $11.00 | $3.11 |
Technical Indicators
Market Signals| Indicator | GFUZ | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 34.43 |
| Support Level | $7.55 | $2.18 |
| Resistance Level | $8.77 | $2.38 |
| Average True Range (ATR) | 0.49 | 0.13 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 25.00 | 6.31 |
Price Performance
Historical ComparisonAbout GFUZ General Fusion Group Ltd. Common Shares
General Fusion Group Ltd is focused on developing fusion energy technology based on Magnetized Target Fusion (MTF), which combines magnetic confinement and mechanical compression to achieve fusion conditions. It operates a large-scale demonstration system, Lawson Machine 26 (LM26), intended to validate elements of its technology and support the development of commercial fusion power plants for electricity generation.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.